New developments in self-injection therapy for erectile dysfunction.
Gingell
J C
JC
Bristol Urological Institute, Southmead Hospital, UK.
D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects; D015740:Calcitonin Gene-Related Peptide / Q000008:administration & dosage; D002746:Chlorpromazine / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D008297:Male; D013948:Moxisylyte / Q000008:administration & dosage; D010208:Papaverine / Q000008:administration & dosage; D017060:Patient Satisfaction; D010646:Phentolamine / Q000008:administration & dosage; D012646:Self Administration; D013565:Sympatholytics / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
D013565:Sympatholytics; D014665:Vasodilator Agents; D014660:Vasoactive Intestinal Peptide; D010208:Papaverine; D000527:Alprostadil; D015740:Calcitonin Gene-Related Peptide; D013948:Moxisylyte; D002746:Chlorpromazine; D010646:Phentolamine